المؤلفون: Andrew Zelenetz, Js, Abramson, Rh, Advani, Cb, Andreadis, Jc, Byrd, Ms, Czuczman, Fayad L, Forero A, Mj, Glenn, Jp, Gockerman, Li, Gordon, Nl, Harris, Rt, Hoppe, Sm, Horwitz, Ms, Kaminski, Yh, Kim, As, Lacasce, Ti, Mughal, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Jm, Vose, Wg, Wierda, Yahalom J, Yunus F

المصدر: Europe PubMed Central

مصطلحات موضوعية: Lymphoma, Non-Hodgkin, Humans, Neoplasm Staging

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e8e00df83cbdacf02ae0bdc6935dd686
https://pubmed.ncbi.nlm.nih.gov/20202462

المؤلفون: L McNeill, CA Estrada, C Ransdell, J Spillane, JC Byrd

المصدر: Journal of Investigative Medicine. 52:S280-S281

مصطلحات موضوعية: General Medicine, General Biochemistry, Genetics and Molecular Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89c2acf0f0982930d0f8a788da1d6900
https://doi.org/10.1097/00042871-200401001-00688

المؤلفون: Jc, Byrd, Lawrence D, Dc, Arthur, Mj, Pettenati, Tantravahi R, Mazin Qumsiyeh, Stamberg J, Fr, Davey, Ca, Schiffer, Cd, Bloomfield

المصدر: Europe PubMed Central

مصطلحات موضوعية: Adult, Male, Antimetabolites, Antineoplastic, Adolescent, Age Factors, Cytarabine, Trisomy, Middle Aged, Survival Analysis, Cohort Studies, Treatment Outcome, Leukemia, Myeloid, Acute Disease, Humans, Female, Prospective Studies, Aged, Chromosomes, Human, Pair 8

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::dc3281a5bb36b17cf940a01cb6519e47
http://europepmc.org/abstract/med/9607582

المؤلفون: Zy, Xu-Monette, Li L, Jc, Byrd, Kj, Jabbar, Gc, Manyam, Cm, Winde, van den Brand M, Alexandar Tzankov, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Kl, Richards, Ed, Hsi, Ww, Choi, Huh J, Ponzoni M

المصدر: Europe PubMed Central

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::03e21ba6244cb12886dc2368b215db53
http://europepmc.org/abstract/med/27760757

المؤلفون: Gambril JA; Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH, USA. alangambril@gmail.com.; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA. alangambril@gmail.com., Ghazi SM; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA., Sansoterra S; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA., Ferdousi M; Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH, USA., Kola-Kehinde O; Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH, USA., Ruz P; Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH, USA., Kittai AS; Division of Hematology, The Ohio State University, Columbus, OH, USA., Rogers K; Division of Hematology, The Ohio State University, Columbus, OH, USA., Grever M; Division of Hematology, The Ohio State University, Columbus, OH, USA., Bhat S; Division of Hematology, The Ohio State University, Columbus, OH, USA., Wiczer T; Department of Pharmacy, James Cancer Hospital and Solove Research Institute, Columbus, OH, USA., Byrd JC; Department of Medicine, University of Cincinnati, Cincinnati, OH, USA., Woyach J; Division of Hematology, The Ohio State University, Columbus, OH, USA., Addison D; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA. Daniel.Addison@osumc.edu.; Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA. Daniel.Addison@osumc.edu.

المصدر: Leukemia [Leukemia] 2024 Aug 17. Date of Electronic Publication: 2024 Aug 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

المؤلفون: Ravikrishnan J; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Diaz-Rohena DY; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Muhowski E; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Mo X; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH., Lai TH; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Misra S; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Williams CD; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Sanchez J; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Mitchell A; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Satpati S; Department of Genomic Medicine, MD Anderson Cancer Center, Houston TX., Perry E; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Kaufman T; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Liu C; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Lozanski A; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Lozanski G; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Rogers K; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Kittai AS; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Bhat SA; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Collins MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jain N; Department of Leukemia, MD Anderson Cancer Center, Houston TX., Wierda WG; Department of Leukemia, MD Anderson Cancer Center, Houston TX., Lapalombella R; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH., Tan F; Newave Pharmaceutical Inc., Pleasanton, CA., Chen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Chen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Shen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Anthony SP; Newave Pharmaceutical Inc., Pleasanton, CA., Woyach JA; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH. Jennifer.Woyach@osumc.edu., Sampath D; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX. DSampath@mdanderson.org.

المصدر: Haematologica [Haematologica] 2024 Aug 08. Date of Electronic Publication: 2024 Aug 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

المؤلفون: Hoff FW; UT Southwestern Medical Center, Dallas, Texas, United States., Blum W; Winship Cancer Institute of Emory University, Atlanta, Georgia, United States., Huang Y; The Ohio State University, Columbus, Ohio, United States., Welkie RL; The Ohio State University, Columbus, Ohio, United States., Swords R; OHSU Knight Cancer Institute Center for Hematologic Malignancies, Portland, Oregon, United States., Traer E; Oregon Health & Science University, Portland, Oregon, United States., Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Lin TL; University of Kansas, Fairway, Kansas, United States., Archer KJ; The Ohio State University, Columbus, Ohio, United States., Patel PA; Servier, Westlake, Texas, United States., Collins RH Jr; UT Southwestern Medical Center, Dallas, Texas, United States., Baer MR; University of Maryland, Baltimore, Maryland, United States., Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States., Arellano ML; Winship Cancer Institute of Emory University, Atlanta, Georgia, United States., Stock W; University of Chicago, Chicago, Illinois, United States., Odenike O; The University of Chicago, Chicago, Illinois, United States., Redner RL; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States., Kovacsovics TJ; City of Hope/Phoenix, Goodyear, Arizona, United States., Deininger MW; Versiti Blood Research Institute, Milwaukee, Wisconsin, United States., Zeidner JF; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States., Olin RL; University of California San Francisco, San Francisco, California, United States., Smith CC; University of California--San Francisco, San Francisco, California, United States., Foran JM; Mayo Clinic Florida, Jacksonville, Florida, United States., Schiller GJ; David Geffen School of Medicine at UCLA, Los Angeles, California, United States., Curran E; University of Cincinnati College of Medicine, Cincinnati, Ohio, United States., Koenig KL; The Ohio State University Wexner Medical Center, Columbus, Ohio, United States., Heerema NA; The Ohio State University, Columbus, Ohio, United States., Chen TL; The Ohio State University, Columbus, Ohio, United States., Martycz M; The Ohio State University, Columbus, Ohio, United States., Stefanos M; OSU, Columbus, Ohio, United States., Rosenberg L; The Leukemia and Lymphoma Society, Rye Brook, New York, United States., Druker BJ; Oregon Health & Science University, Portland, Oregon, United States., Levine RL; Memorial Sloan-Kettering Cancer Center, New York, New York, United States., Burd A; The Leukemia and Lymphoma Society, Rye Brook, New York, United States., Yocum AO; The Leukemia and Lymphoma Society, Rye Brook, New York, United States., Borate U; The Ohio State University, Columbus, Ohio, United States., Mims AS; The Ohio State University, Columbus, Ohio, United States., Byrd JC; The University of Cincinnati, Cincinnati, Ohio, United States., Madanat YF; UT Southwestern Medical Center, Dallas, Texas, United States.

المصدر: Blood advances [Blood Adv] 2024 Aug 07. Date of Electronic Publication: 2024 Aug 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

المؤلفون: Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Sharman JP; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR., Ghia P; Division of Experimental Oncology, Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Eyre TA; Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Jurczak W; Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland., Siddiqi T; City of Hope Comprehensive Cancer Center, Duarte, CA., Miranda P; AstraZeneca, Gaithersburg, MD., Shahkarami M; AstraZeneca, South San Francisco, CA., Butturini A; AstraZeneca, South San Francisco, CA., Emeribe U; AstraZeneca, Gaithersburg, MD., Byrd JC; Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.

المصدر: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3345-3359.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Pyrazines*/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/mortality , Benzamides*/therapeutic use, Humans ; Male ; Aged ; Female ; Middle Aged ; Aged, 80 and over ; Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Recurrence ; Clinical Trials as Topic ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage ; Treatment Outcome

المؤلفون: Merchand-Reyes G; Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States., Bull MF; College of Medicine, The Ohio State University, Columbus, OH, United States., Santhanam R; Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States., Valencia-Pena ML; Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States., Murugesan RA; College of Medicine, The Ohio State University, Columbus, OH, United States., Chordia A; College of Medicine, The Ohio State University, Columbus, OH, United States., Mo XM; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, United States., Robledo-Avila FH; Center for Microbial Pathogenesis, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States., Ruiz-Rosado JD; Kidney and Urinary Tract Center, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.; Division of Pediatric Nephrology and Hypertension, Nationwide Children's Hospital, Columbus, OH, United States., Carson WE 3rd; Department of Surgery, The Ohio State University, Columbus, OH, United States., Byrd JC; Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, United States., Woyach JA; Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States., Tridandapani S; Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States., Butchar JP; Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States.

المصدر: Frontiers in immunology [Front Immunol] 2024 Jun 11; Vol. 15, pp. 1409333. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Nod2 Signaling Adaptor Protein*/agonists , Nod2 Signaling Adaptor Protein*/metabolism , Nod2 Signaling Adaptor Protein*/immunology , Receptors, IgG*/metabolism , Receptors, IgG*/immunology , Macrophages*/immunology , Macrophages*/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell*/immunology , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/metabolism, Animals ; Humans ; Mice ; Acetylmuramyl-Alanyl-Isoglutamine/pharmacology ; Female ; Mice, Inbred C57BL ; Signal Transduction ; Phagocytosis ; Rituximab/pharmacology ; Rituximab/therapeutic use

المؤلفون: Kittai AS; Division of Hematology, The Ohio State University, Columbus, OH., Bond D; Division of Hematology, The Ohio State University, Columbus, OH., Huang Y; Division of Hematology, The Ohio State University, Columbus, OH., Bhat SA; Division of Hematology, The Ohio State University, Columbus, OH., Blyth E; Blood Transplant and Cell Therapies Program, Westmead Hospital Department of Haematology, Westmead, NSW, Australia., Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH., Chavez JC; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dela Cruz JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dowling MR; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Melbourne, Australia., Duffy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Ho C; Clinical Research Division, Fred Hutchinson Cancer Center and University of Washington, Seattle, WA., Jacobson C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Jaglowski S; Division of Hematology, The Ohio State University, Columbus, OH., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Lin KH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Miller C; Department of Pathology, The Ohio State University, Columbus, OH., McCarthy C; Department of Hematology, Department of Clinical Informatics, City of Hope National Medical Center, Duarte, CA., Omer Z; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH., Parry E; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Rai M; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Rogers KA; Division of Hematology, The Ohio State University, Columbus, OH., Saha A; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Schachter L; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Scott H; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Shadman M; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Melbourne, Australia., Siddiqi T; Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA., Stephens DM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Vanguru V; Institute of Haematology, Royal Prince Alfred Hospital, NSW, Australia., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Woyach JA; Division of Hematology, The Ohio State University, Columbus, OH., Thompson PA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Melbourne, Australia.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 10; Vol. 42 (17), pp. 2071-2079. Date of Electronic Publication: 2024 Mar 29.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antigens, CD19*/therapeutic use , Antigens, CD19*/immunology , Immunotherapy, Adoptive*/adverse effects , Immunotherapy, Adoptive*/methods , Receptors, Chimeric Antigen*/therapeutic use , Receptors, Chimeric Antigen*/immunology, Humans ; Retrospective Studies ; Male ; Middle Aged ; Aged ; Adult ; Female ; Aged, 80 and over ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Progression-Free Survival